Proprietary Blend of Five Live Probiotic Strains Shown to
Help Reduce Severity and Frequency of Common, Occasional GI
Symptoms*
Now Rolling out to Major U.S. Retailers
LAVAL, QC, April 8, 2021 /PRNewswire/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced
the U.S. launch of its novel daily over-the-counter probiotic
supplement, ENVIVE™. ENVIVE™ is shown to help reduce the severity
and frequency of five occasional gastrointestinal (GI) symptoms -
diarrhea, constipation, gas, bloating and discomfort - and help
strengthen and protect the digestive system by strengthening the
gut barrier. ENVIVE™ is proven to help relieve these occasional GI
symptoms in as little as two weeks.*
"The launch of ENVIVE™ is another key example of Bausch Health's
continued focus on bringing new products to market that help
fulfill patients' needs," said Joseph C.
Papa, chairman and CEO, Bausch
Health. "Research indicates that approximately 61% of
Americans have experienced one or more GI symptoms in the past
week.1 Leveraging our scientific knowledge and
legacy of innovation in GI research, we specifically developed and
clinically tested ENVIVE™ to offer consumers a new
preservative-free, multi-strain probiotic designed to help relieve
five occasional GI symptoms."
In a healthy gut, probiotics or live organisms, help maintain a
healthy balance of "good" and "bad" bacteria. Stress and poor diet,
among other causes, can disrupt this balance, which can negatively
affect overall digestive health. Probiotic supplements contain
"good" bacteria that, when consumed, can help restore the balance
and may help protect the GI tract from harmful microorganisms that
can negatively affect digestion and gut function. In a four-week
study, participants taking ENVIVE™ experienced a reduction in the
severity and frequency of five occasional GI symptoms at both weeks
two and four, and 85% reported improved overall GI well-being.
ENVIVE™ was also shown to help strengthen the gut barrier.
"Many of my patients experience common, occasional GI
disturbances due to stress, poor diet or other lifestyle factors,
particularly in today's difficult times," said Reed B. Hogan, II, M.D., a gastroenterologist
from GI Associates & Endoscopy Center, Flowood, Miss. "Only ENVIVE™ has this unique
blend of five clinically studied probiotic strains that have been
shown to help strengthen the digestive system and reduce occasional
GI symptoms."*
ENVIVE™ will be available for purchase at most national
retailers, including Target, CVS, Kroger, Walmart, Rite Aid and
Amazon, and will have a manufacturer's suggested retail price of
$16.99 (15-count).
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
*These statements
have not been evaluated by the Food and Drug Administration. This
product is not intended to diagnose, treat, cure or prevent any
disease.
|
References
- Almario CV, Ballal ML, Chey WD, et al. Burden of
gastrointestinal symptoms in the United
States: results of a nationally representative survey of
over 71,000 Americans. Am J Gastroenterol.
2018;113(11):1701-1710. doi:10.1038/s41395-018-0256-8.
®/TM are trademarks of Bausch Health Companies Inc. or
its affiliates.
Any other product/brand names and/or logos are trademarks of the
respective owners.
© 2021 Bausch Health Companies Inc. or
its affiliates.
ENV.0040.USA.21
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch-health-launches-envive-daily-probiotic-supplement-301264738.html
SOURCE Bausch Health Companies Inc.